Gene-gene, gene-environment & multiple interactions in colorectal cancer

Journal of Environmental Science and Health - Part C Environmental Carcinogenesis and Ecotoxicology Reviews

Volumn 24, Issue 1, 2006, Pages 1-101

  Ahmed, Farid E ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Alcohol; Apoptosis; Epigenetic; Exercise; Fruit; HRT; Imprinting; Meat; Mitochondria; MSI; Mutations; Nutrigenomics; Polymorphism; Smoking; SNP; Transcription Factors; Vegetables

Indexed keywords

BIOMARKERS; DISEASES; FRUITS; RISK ASSESSMENT; TUMORS;

APOPTOSIS; EPIGENETIC; EXERCISE; MUTATIONS;

GENETIC ENGINEERING;

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ALCOHOL; ALPHA TOCOPHEROL; AMINO ACID; BIOLOGICAL MARKER; CALCINEURIN; CALCIUM; CYANOCOBALAMIN; CYTOCHROME P450; ESTROGEN; FATTY ACID; GLUCOSE; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; RETINOL; SOMATOMEDIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRACE ELEMENT; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; UPSTREAM STIMULATORY FACTOR; VITAMIN D; VITAMIN D RECEPTOR; ZINC;

ALCOHOL CONSUMPTION; APOPTOSIS; CANCER RISK; CELL DEATH; CELL RENEWAL; COLON CARCINOGENESIS; COLON MUCOSA; COLORECTAL CANCER; DIETARY INTAKE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; EVALUATION; EXERCISE; FRUIT; GENE GENE INTERACTION; GENE MUTATION; GENE SEQUENCE; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOME IMPRINTING; GENOMICS; GENOTYPE ENVIRONMENT INTERACTION; HETEROZYGOSITY LOSS; HOMEOSTASIS; HORMONE SUBSTITUTION; HUMAN; INHERITANCE; MACRONUTRIENT; MEAT; MICROSATELLITE INSTABILITY; MITOCHONDRION; NUTRIGENOMICS; NUTRITIONAL DEFICIENCY; ONCOGENE K RAS; PROTEOMICS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; VEGETABLE;

COCARCINOGENESIS; COLORECTAL NEOPLASMS; ENVIRONMENT; HUMANS; LIFE STYLE;

CANCERS; FRUITS; GENES; GENETIC ENGINEERING; MITOCHONDRIA; RISK ASSESSMENT;

EID: 33646810079     PISSN: 10590501     EISSN: 15324095     Source Type: Journal    
DOI: 10.1080/10590500600614295     Document Type: Review

References (390)

1. Wang TL, Rago C, Silliman N. Prevelance of somatic alterations in the colorectal cancer genome. Proc Natl Acad Sci USA 2002;99:3076-3080.
2. Vineis P. Cancer as an evolutionary process at the cell level: an epidemiological perspective. Genomics 2003;24:1-6.
3. Veneis P, Marullo G, Mauguerra M. An evolutionary paradigm for carcinogenesis? J Epidemiol Commun Health 2003;57:89-95.
4. Wright NA. Cell proliferation in carcinogenesis. In: Alison M, ed. Cancer Handbook. London: McMillan Publishers, 2002, 114-125.
5. Jorde LB, Watkins WS, Carlson M, Groden J, Albertsen H, Thliveris A, Leppert M. Linkage disequilibrium predicts physical distance in the adenomatous plyposis coli region. Am J Hum Genet 1994;54:884-898.
6. Hardy GH. Mendalian proportions in mixed population. Science 1908;28:49-50.
7. Weinberg W. Über den Nachweis der Vererbung beim Mensche Jh Ver vater.l Naturk Württemb 1908;64:369-282.
8. Shoemaker J, Painter I, Weir BS. A Bayesian characterization of Hardy-Weinberg disequilibrium. Genetics 1998;149:209-2088.
9. Dean M. Approaches to identify genes for complex human diseases. Hum Mutat 2003;22:261-274.
10. Nagase H, Mao JH, de Koning JP, et al. Interactions between skin tumor modifier loci in interspecific (spretus/musculus) backcross mice. Cancer Res 2001;61:1305-1308.
11. Houlson RS, Peto J. The search for low penetrance cancer susceptibility alleles. Oncogene 2004;6471-6476.
12. Moisio AL, Sistonen P, Mecklin JP, et al. Genetic polymorphism in carcinogen metabolism and their association to hereditary nonpolyposis colon cancer. Gastroenterology 1998;115:1387-1394.
13. Kong S, Amos CL, Luthra R, et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249-252.
14. Reitmair AH, Cai JC, Bjerknes M et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 1996;56:2922-2926.
15. Toft NJ, Winton DJ, Kelly J, et al. Mshe status modulates both apoptosis and mutation frequency in the murine small intestine. Proc Natl Acad Sci USA 1999;96:3911-3915.
16. Markowitz S. TGF-beta receptors and DNA repair genes, coupled targets in a pathway of human colon carcinogenesis. Biochim Biophys Acta 2000;1470:M13-M20.
17. Mitchell RJ, Farrington SM, Dunlop G, et al. Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review. Am J Epidemiol 2002;156:885-902.
18. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
19. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998;280:1036-1037.
20. Shields PG, Harris CC. Cancer risk and low penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000;18:7f.2309-2315.
21. Goldman R, Shields PG. Food mutagens. J Nutr 2003;133:965S-973S.
22. Yang Q, Khoury M. Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research. Epidemiol Rev 1997;19:33-43.
23. Vineis P. Molecular epidemiology: low-dose carcinogens and genetic susceptibility. Int J Cancer 1997;71:1-3.
24. Khoury MJ, Wagener DK. Population and familial relative risks of disease associated with environmental factors in the presence of gene-environment interaction. Am J Epidemiol 1993;137:1241-1250.
25. Holston R, Tomlinson IPM. Polymorphism and colorectal tumor risk. Gastroenterology 2001;121:282-301.
26. Botto LD, Khoury MJ. Commentary: facing the challenge of gene-environment interaction: the two-by-four tables and beyond. Am J Epidemiol 2004;153:1016-1020.
27. Khoury MJ, Yang Q, Gwinn M, et al. An epidemiologic assessment of genomic profile for measuring susceptibility to common disease and targeting interactions. Genet Med 2004;6:38-47.
28. Ahmed FE, Vos P, Holbert D. Modeling survival in colon cancer: a methodological review. Cancer Detect Prev 2005; (in press).
29. Ahmed FE. Artificial neural networks for diagnosis and survival predictin in colon cancer. Mol Cancer 2005; (in press).
30. Smith DG, Ebrahim S, "Mendelian randomization": can genetic epidemiology contribute to understanding environmental determinants of disease. Int J Epidemiol 2003;2:1-22.
31. Clayton D, McKeigue PM. Epidemiologic methods for studying genes and environmental factors in complex diseases. Lancet 2001;358:1356-1360.
32. Little J, Sharp L, Duthie S, Narayanan S. Colon cancer and genetic variation in folate metabolism: the clinical bottom line. J Nutr 2003;:3758S-3766S.
33. Willett WC. Balancing life-style and genomics research for disease prevention. Science 2002;296:695-698.
34. Müller M, Kersten S. Nutrigenomics: goals and strategies. Nature Rev Genet 2003;4:315-322.
35. Vineis P, Schulle P, McMichael AJ. Misconceptions about the use of genetic tests in populations. Lancet 2001;357:709-712.
36. Evans JP, Skrzynia C, Burk W. The complexties of predictive genetic testing. Br M J 2001;322:1052-1056.
37. Vineis P. A self-fulfilling prophecy: are we underestimating the role of the environment in gene-environment interaction research? Int J Epidemiol 2004;33:945-946.
38. Sanderson P, Johnson IT, Mathers JC, et al. Emerging diet-related surrogate end points for colorectal cancer in UK Food Standards Agency diet and colonic health work-shop report. Br J Nutr 2004;91:315-320.
39. Ahmed FE. Molecular techniques for studying gene expression in carcinogenesis. J Env Sci Health 2002;C20:77-116.
40. Ahmed FE. Development of novel diagnostic and rognestic molecular markers for sporadic colon cancer. Exp Rev Mol Diag 2005;5:337-352.
41. Andrieu N, Goldstein AM. Epidemiologic and genetic approaches in the study of gene-environment interaction: an overview of available methods. Epidemiol Rev 1998;20:137-147.
42. Bonaïti-Pellié C. Methodological aspects of investigating gene-nutrient interactions. Eur J Cancer Prevent 2002;11:69-74.
43. Milner JA, Allison RG, Elliott JG, et al. Opportunities and challenges for future mutation research in cancer prevention: a panel discusson. J Nutr 2003;133:252S-2504S.
44. Mathers JC. The biological revolution - towards a mechanistic understanding of the impact of diet on cancer risk. Mutat Res 2004;551:20.43-49.
45. Andrieu N, Goldstein AM, Thomas DC, et al. Counter-matching in studies of gene-environment interactions: efficiency and feasibility. Am J Epidemiol 2001;153:265-274.
46. Schaid DJ. Case-parents design for gene-environment interactions. Genet Epidemiol 1999;16:261-273.
47. Hemminki K, Lönnstedt I, Vaittines P, et al. Estimation of genetic and environmental components in colorectal and lung cancer and melanoma. Genet Epidemiol 2001;20:107-116.
48. Potter JD. Epidemiology, cancer genetics and microarrays in making correct inferences, using appropriate design. Trends Genet 2003;19:690-695.
49. Ahmed, FE. Colorectal cancer: prevelance, screening, gene expression and mutation, and risk factors and assessment. Environ Carcino Ecotox Revs 2003;C21:65-131.
50. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999;91:916-932.
51. Ahmed, FE. Effect of diet, life style, and other environmental/ chemopreventive factors on colorectal cancer development and assessment of the risks. Environ Carcino Ecotox Revs 2004;C22:91-147.
52. Keku TO, Millikan RC, Marti C, et al. Family historyof colon cancer. What does it mean and how is it useful? Am J Prev Med 2003;24:170-176.
53. Lichtenstein P, Holm N, Verkassalo PK, et al. Environmental and heritable factors in the causation of cancer - analysis of cohorts of tumors from Sweden, Denmark, and Finland. N Engl J Med 2000;343:28-85.
54. Breivik J, Gandernack G. Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer. Adv Cancer Res 1999;76:182-212.
55. Cortessis V, Thomas DC. Toxicokinetic genetics: an approach to gene-environment and gene-gene interactions in complex metabolic pathways. IARC Sci Publ 2004;157:127-150.
56. De Roos AJ, Smith MJ, Chanock S, et al. Toxicological considerations in the application and interpretation of susceptibility biomarkers in epidemiologic studies. IARC Sci Publ 2004;157:105-125.
57. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (iDDM). Am J Hum Genet 1993;52:506-516.
58. Jnapp M. The transmission/disequilibrium test and parental-genotype reconstruction: the reconstruction-combined transmission/disequilibrium test. Am J Hum Genet 1999;64:861-870.
59. Ulrich CM, Robien K, Mcleod H. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nature Rev Cancer 2003;3:912-920.
60. Loktionov A. A common gene polymorphism, cancer, progression and prognosis. Cancer Lett 2004;208:1-33.
61. Grate S, Gaspaxi L, Alexandrie A-K, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomark Prev 2001;10:1239-1248.
62. Nerbert DW. Role of genetics and drug metabolism in human cancer risk. Mutat Res 1991;247:267-281.
63. Sivaraman L, Leatham MP, Yee J, et al. CYP1A1 genetic polymorphism and in situ colorectal cancer. Cancer Res 1994;54:3692-3695.
64. Boobis AR, Lynch AM, Murray S, et al. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens in their major route of metabolism in humans. Cancer Res 1994;54:89-94.
65. Sachse C, Smith G, Wilkie MJV, et al. A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 2002;23:1839-1849.
66. Slattery ML, Samowitz W, Ma K, et al. CYP1A1, cigarette smoking, and colon and rectal cancer. Am J Epidemiol 2004;160:842-852.
67. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002;506-507:65-77.
68. Hein DW. N-acetyltransferase genetics and their role in predisposition to aromatic and heterocyclic amine-induced carcinogenesis. Tox Lett 2000;112-113:349-356.
69. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the MAT1 and NAT2 acetylation polymorphism. Cancer Epidemiol Biomark Prev 2000;9:29-42.
70. Ye Z, Parry JM. Meta-analysis of 20 case-control studies in the N-acetyltransferase 2 acetylation status and colorectal cancer risk. Med Sci Monit 2002;8:558-565.
71. Ilett KF, David BM, Detchon P, et al. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987;47:1466-1469.
72. Wohlleb JC, Hunter CF, Blass B, et al. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. Int J Cancer 1990;46:22-30.
73. Ladero JM, Gonzalez JF, Benítez, et al. Acetylator polymorphism in human colorectal carcinoma. Cancer Res 1991;51:2098-2100.
74. Rodriguez JW, Kirlin WG, Ferguson RJ, et al. Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch Toxicol 1993;67:445-452.
75. Shibata K, Nakasima T, Abe M, et al. Molecular genotyping for N-acetylation polymorphism in Japanese patients with colorectal cancer. Cancer 1994;74:3108-3112.
76. Lang NP, Butler MA, Messengill J, Lawson M, Stotts RC, Hauer-Jensen M, Kadlubar FF. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increases the risk for colorectal cancer or polyps. Cancer Epidemiol Biomark Prev 1994;3:675-682.
77. Oda Y, Tanaka M, Nakanishi I. Relation between the occurrence of K-ras gene point mutation and genotypes of polymorphic N-acetyltransferase in human colorectal carcinomas. Carcinogenesis 1994;15:1365-1369.
78. Bell DA, Stephens EA, Gastranio T, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995;55:3537-3542.
79. Spurr NK, Gough AC, Chinegwundoh FI, et al. Polymorphism in drug-metabolizing enzymes as modifiers of cancer risk. Cin Chem 1995;41:1864-1869.
80. Welfare MR, Cooper J, Bassendine MF, et al. Relationsip between acetylator status, smoking, dier and colorectal cancer risk in the northeast of England. Carcinogenesis 1997;18:1351-1354.
81. Hubbard AI, Harrison DJ, Moyes C, et al. N-acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancer with chromosome 8p deletions. Gut 1997;41:229-234.
82. Chen JS, Stampfer MJ, Hough HL, et al. A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. Cancer Res 1998;58:307-3311.
83. Gil JP, Lechner MC. Increased frequency of wild-type arylamine- N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis 1998;19:37-41.
84. Lee ED, Zhao B, Seow-Cheh F. Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in Chinese population. Pharmacogenetics 1998;8:513-517.
85. Yoshioka M, Katoh T, Nakano M, et al. Glutathione S-transferase (GST) M1, T1, P1, N-acetyltransferase (NAT) 1 and 2 genetic polymorphisms and susceptibility to colorectal cancer. J UOEH 1999;21:133-147.
86. Potter JD, Bigler J, Fosdick et al. Colorectal adenomatous nd hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiol Biomark Prev 1999;8:69-75.
87. Slattery ML, Potter JD, Ma K-N, et al. Western diet, family history of colorectal cancer. Cancer Causes Control 2000;11:1-8.
88. Agundez JAG, Lozano L, Ladero JM, et al. N-acetyltranserase 2 (NAT2) genotype and colorectal carcinoma: risk variability according to tumor site? Scand J Gastroenterol 2000;35:1087-1091.
89. Butler W, Ryan P, Roberts-Thomson IC. Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol 2001;16:631-635.
90. Ishibe N, Sinha R, Hein DW, et al. Genetic polymorphism in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 2002;12:145-150.
91. Lin HJ, Probst-Hensch NM, Hughes NC, et al. Variants of N-acetylytransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenomics 1998;8:269-281.
92. Probst-Hensch NM, Haile RW, Ingles SA et al. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Res 1995;55:2017-2020.
93. Brockton N, Little J, Sharp L, et al. N-acetyltransferase polymorphism and colorectal cancer. A HuGE review. Am J Epidemiol 2000;151:846-861.
94. Keku TO, Millikan RC, Marti C, et al. Family historyof colon cancer. What does it mean and how is it useful? Am J Prev Med 2003;24:170-176.
95. Coughtrie MWH, Johnston LE. Interactions between dietary chemicals and human sulfotransferases - molecular mechanisms and clinical significance. Drug Metab Dispos 2001;29:522-528.
96. Coughtrie MWH, Gillsen RAHJ, Shek B, et al. Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 1999;337:45-49.
97. Raftogianis RB, Wood TC, Weinshillboum RM. Human phenol sulfotransferases SULT1A2 and SULT1A1. Genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol 1999;58:605-616.
98. Bamber DE, ryer AA, Strange RC, et al. Phenol sulphotransferase SULT1A*1 genotype is associated with reduction of risk of colorectal cancer. Pharmacogenetics 2001;11:679-685.
99. Tiemersma EW, Bunschoten A, Kok FJ, et al. Effect of SULT1A2 andNAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenoma. Int J Cancer 2004;108:97-103.
100. Frame LT, Gatlin TL, Kadlubar FF, et al. Metabolic differences and their impact on human disease: sulfotransferase and colorectal cancer. Environ Toxicol Pharmacol 1997;4:277-281.
101. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST* and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Biol 1995;30:445-600.
102. Cotton SC, Sharp L, Little J, et al. Glutathione S-transferase polymorphism and colorectal cancer: a HuGE review. Am J Epidemiol 2000;151:7-32.
103. Lin HJ, Probst-Hensch NM, Louie AD, et al. Glutathione S-transferase null phonotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomark Prev 1998;7:647-652.
104. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotype GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomark Prev 1997;6:733-743.
105. Lin HJ, Han CY, Bernstein DA, et al. Ethnic distribution of the glutathione S-transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis 1994;15:1077-1081.
106. Mukanganyama S, Masimirembwa CM, Naik YS, et al. Phenotyping of the glutathione S-transferase M1 polymorphism in Zimbabweans and the effects of chlorquine on blood glutathione S-transferase m1 and A. Clin Chim Acta 1997;265:145-155.
107. Lin HJ, Zhou H, Dai A, et al. Glutathione transferase GSTT1, broccoli and prevalence of colorectal adenomas. Pharmacogenetics 2002;12:175-179.
108. Welfare M, Adeokun, AM, Bassendine MF, et al. Polymorphism in GSTP1, GSTM1 and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomark Prev 1999;8:289-292.
109. Loktinov A, Watson MA, Gunter M, et al. Glutathione-S-transferase gene polymorphism in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele cariants as a risk-modulation factor. Carcinogenesis 2001;23:1053-1060.
110. Lüchtenbory M, Weijenbery MP, Kampman E, et al. Cigarette smoking and colorectal cancer: APC mutations, hMLH1 expression, and GSTM1 polymorphism. Am J Epidemiol 1005;161:86-816.
111. Kim Y-I. Folate and carcinogenesis: Evidence, mechanism, and implications. J Nutr Biochem 1999;10:66-88.
112. Ulrich CM, Robien K, Sparks R. Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenetics 2002;3:299-313.
113. Yi P, Melnyk S, Pogribna M, et al. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000;275:29318-29323.
114. Wang X, Duarte N, Cai H, et al. Relationship between total plasma homocysteine, polymorphism of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 1999;146:133-140.
115. Slattery M, Potter J, Samowitz W, et al. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomark Prev 1999;8:513-518.
116. Shannon B, Gnanasampanthan S, Beilby J, et al. A polymorphism in the methylenetetrahydrofolate reductase gene predisposes to colorectal cancers with microsatellite instability. Gut 2002;50:520-524.
117. Ma J, Stampfer MJ, Giovannucci E, et al. Methylentetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-1162.
118. Chen J, Hunter D, Stampfer M, et al. A prospective study on relations of a polymorphism in the thymidylate synthase promoter enhancer region and the risk and survival of colorectal cancer. Cancer Epidemiol Biomark Prev 2003;12:953-957.
119. Garrow T, Brenner A, Whitehead V, et al. Cloning of human cDNAs encoding mitochondrial and cytosolic serine hydroxymethyltransferases and chromosomal location. J Biol Chem 1993;268:11910-11916.
120. Heil S, van Der Put N, Waas E, et al. Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? Mol Genet Metab 2001;73:164-172.
121. Chen J, Kyte C, Valain M, et al. Polymorphism in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int J Cancer 2004;110:617-620.
122. Curtin K, Bigler J, Slattery M, et al. MTHFR C677T and A1298C polymorphism: diet, estrogen and risk of colon cancer. Cancer Epidemiol Biomark Prev 2004;13:285-292.
123. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomark Prev 1999;8:659-668.
124. Chen J, Giovannucci E, Kelsey K, et al. A methylentetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4864.
125. Levine AJ, Siegmund KD, Erwin CM, et al. The methylentetrahydrofolate reductase polymorphism and distal colorectal cancer risk. Cancer Epidemiol Biomark Prev 2000;9:657-663.
126. Halstead CH, Villaneuva JA, Devlin AM, et al. Metabolisc interactions of alcohol and folate. J Nutr 2002; 132: 2367S-2372S.
127. Goode EL, Potter JD, Bigler J, et al. Methionine synthase D919G polymorphism, folate metabolism and colorectal adenoma risk. Cancer Epidemiol Biomark Prev 2004;13:157-162.
128. Chen J, Ma J, Stampfer MJ, et al. Linkage disequilibrium between the 677C>T and 1298A>C polymorphism in human methylentetrahydrofolate reductase gene and their contribution to risk of colorectal cancer. Cancer Epidemiol Biomark Prev 2002;11:339-342.
129. Murtaugh M, Ssaki W, ven den Berg W, et al. Dietary intake of folate and riboflavin, MTHFR C677TT genetics and colorectal adenoma risk: a Dutch case-control study. Cancer Epidemiol Biomark Prev 2005;14:1562-1566.
130. Chen J, Giovannucci E, Hankinson SE, et al. A prospective study of methylentetrahydrofolate reductase and methionine synthase gene polymorphism and risk of colorectal adenoma. Carcinogenesis 1998;19:2129-2132.
131. Giovannucci E, Chen J, Smith-Warner SA, et al. Methylentetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenoma. Cancer Epidemiol Biomark Prev 2003;12:970-979.
132. Ulvik A, Evensen ET, Lien EA, et al. Smoking, folate and methylentetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am J Med Genet 2001;101:246-254.
133. Marugame T, Tsuji E, Kiyohara C, et al. Retention of plasma folate and methylentetrahydrofolate reductase C677T polymorphism to colorectal adenomas. Int J Epidemiol 2003;32:64-66.
134. Yang Q, Khoury MJ, Botto L, et al. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet 2003;72:636-649.
135. Ngothu KK, Jaszewski R, Moragoda L, et al. Folic acid mediated attenuation of loses of heterozygosity of DCC tumor suppressor gene in the colonic mucosa of patients with colorectal adenomas. Cancer Detect Prevent 2003;27:297-304.
136. Crott JW, Mashiyama SJ, Ames BN, et al. The effect of folic acid deficiency and MTHFR C677T polymorphism on chromosome damage in human lymphocyte in vitro. Cancer Epidemiol Biomark Prev 2001;10:1089-1096.
137. Seitz HK, Oneta CM. Gastrointestinal alcohol dehydrogenase. Nutr Rev 1998;56:52-60.
138. Estonias M, Svensson S, Hõõg JO. Alcohol dehydrogenase in human tissues: location of transcripts coding for five classes of the enzyme. FEBS Lett 1996;397:338-342.
139. Borràs E, Coutelle C, Rosell A, et al. Genetic polymorphism of alcohol dehydrogenase in Europeans: the ADH*2 allele decreases the risk for alcoholism and is associated with ADH*1. Hepatology 2000;31:984-989.
140. Suzuki K, Uchida A, Mizoi Y, et al. Study on ADH2 and ALDH2 genotyping by PCR-RFLP and SSCP analyses with description of allele and genotype frequencies in Japanese, Finn and Lapp populations. Alcohol Alcohol 1994; 29 (Suppl 1): 21-27.
141. Tiemersma EW, Wark PK, Ocké MC, et al. Alcohol consumption, alcohol dehydrogenase 3 polymorphism, and colorectal sdenoma. Cancer Epidemiol Biomark Prev 2003;12:419-425.
142. Frezza M, Di Padova C, Pozzato G, et al. The role of decreased gastric alcohol dehydrogenase activity and first class metabolism. N Engl J Med 1990;322:95-99.
143. Foppa I and Spiegelman D. Power and sample size calculations for case-control studies on gene-environment interactions with a polytomous exposure variable. Am J Epidemiol 1997;146:596-604.
144. Nosova T, Jousimies-Somer H, Kaihovaara P, et al. Characteristics of aldehyde dehydrogenases of certain aerobic bacteria representing human colonic flora. Alcohol Clin Exp Res 1997;21:489-494.
145. Salaspuro M. Microbial metabolism of ethanol and acetaldehyde and clinical consequences. Addict Biol 1997;2:35-46.
146. Lieber CS. Ethanol metabolism, cirrhosis and alcoholism. Clin Chim Acta 1997;257:59-84.
147. Vanden Heuvel JP. Peroxisome proliferators-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis. J Nutr 1999;129:575S-580S.
148. Girnun GD, Smith WM, Dori S, et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA; 99: 13771-13776.
149. Braissant O, Foufelle F, Scotto C, et al. Differential expression of peroxisome proliferators-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-366.
150. Pineau T, Hudgins WR, Liu L, et al. Activation of a human peroxisome proliferators-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem Pharmacol 1996;52:659-667.
151. Siezen CLE, van Leeuwen IM, Kram NR et al. Colorectal adenoma risks is modified by the interplay between polymorphism in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005;26:449-457.
152. James ML, Gibson RA, Cleland LG. Dietary plyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71:343S-348S.
153. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433-440.
154. Juvonen T, Kenvinen K, Kairaluoma MI, et al. Gallstone cholesterol content is related to apolipoprotein E polymorphism. Gastroenterology 1993;104:1806-1813.
155. Vogel T, Guo N-H, Guy R, et al. Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994;54:299-308.
156. Lipkin M, Reddy B, Newmark H, et al. Dietary factors in human colorectal cancer. Ann Rev Nutr 1999;19:545-586.
157. Kervinen K, Södervik H, Mäkelä J, et al. Is the development of adenoma and carcinoma in proximal colon related to apolipoprotein-E phenotype? Gastroenterology 1996;110:1785-1790.
158. Butler WJ, Ryan P, Roberts-Thomson JC. Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol 2001;16:631-635.
159. Watson MA, Gay L, Stebbings WSL. Apolipoprotein E gee polymorphism and colorectal cancer: gender specific modulation of risk and prognosis. Clin Sci 2003;104:537-545.
160. Rex DK. Colonoscopy: a review of its yield for cancer and adenomas by indication. Am J Gastroenterol 1995;90:353-365.
161. Fernandez E, Bosetti C, La Vecchia C, et al. Sex differences in colorectal cancer and mortality in Europe, 1955-1996. Eur J Cancer Prev 2000;9:99-104.
162. Ng MKC, Jessup W, Celermajer DS. Sex-related differences in the regulation of macrophage cholesterol metabolism. Curr Opin Lipidol 2001;12:505-510.
163. Enocksson S, Shimizu M, Lonnqvist F, et al. Demonstration of an in vivo functional beta 3-adrenoreceptor in man. J Clin Invest 1995;95:2239-2245.
164. Green SA, Turki J, Hall IP, et al. Implications of genetic variability of human beta 2-adrenergic receptor structure. Pulm Pharmacol 1995;8:1-10.
165. Sakane N, Yoshida T, Umekawa T, et al. Beta2-adrenoreceptor gene polymorphism and obesity. Lancet 1999;353:1976-1984.
166. Walston J, Silver K, Bogardus C, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 1995;333:343-347.
167. Takezaki T, Hamajima N, Matsuo K, et al. Association of polymorphism in the beta-2 and beta-3 adrenergic receptor genes with risk of colorectal cancer in Japanese. Int J Clin Oncol 2001;6:117-127.
168. Ahmed fE. Molecular markers for early cancer detection. J Env Sci Health 2000;C18:75-125.
169. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998;5:1-7.
170. Betticher DC, Thatcher N, Altermatt HJ, et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;1005-1011.
171. Matthias C, Branigan K, Jahnke V, et al. Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 1998;4:2411-2418.
172. Kong S, Amos CI, Luthra R, et al. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal carcinoma. Cancer Res 2000;60:249-252.
173. Kong S, Wei Q, Amos CI, et al. Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Nat Cancer Inst 2001;93:1106-1108.
174. Thomas M, Kalita A, Labrecque S, et al. Matlashewski G. Two polymorphic variants of wild-type p53 difer biochemically and biologically. Mol Cell Biol 1999;19:1092-1100.
175. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998;393:229-234.
176. Ahmed FE, Molecular methods for detection of mutations. J Env Sci Health 1998; C16:47-80.
177. Jones JS, Chi X, Gu X, et al. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in Caucasian populations. Clin Cancer Res 2004;10:5845-5849.
178. Gemignani F, Moreno V, Landi S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;23:1954-1956.
179. Ahmed FE. Colon cancer: molecular staging models that characterize risk and enhance prgnosis. Cancer Genom Proteo 2004;1:2019-2036.
180. Andreasen PA, Kjøller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
181. Nielsen HJ, Pappot H, Christensen IJ, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. Br Med J 1998;316:829-830.
182. Dawson SJ, wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to IL-1 in Hep G2 cells. J Biol Chem 1993;268:10739-10745.
183. Loktionov A, Watson MA, Slebbings WSL. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett 2003;189:189-196.
184. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology 2002;16:217-226.
185. Rhodes JM, Campbell BJ. Inflammation and colorectal cancer. IBD-associated and sporadic cancer compared. Trend Mol Med 2003;8:10-16.
186. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphism in inflammatory genes interlukin (IL)6, rL6, tumor necrosis factor α, NFKB1 and peroxisome proliferators-activated receptor γ with colorectal cancer. Cancer Res 2003;63:3560-3566.
187. Hansen-Petrk MB, McEntee MF, Jull B, et al. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Mm/+) mice. Cancer Res 2002;62:403-408.
188. Lin HJ, Lakkides KM, Keku TO, et al. Prostaglandin H synthase variant (Va511la) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomark Prev 2002;11:1305-1315.
189. Wiesner GL, Platzer P, Buxbaum S, et al. Testing for colon neoplasia susceptibility variants at the human COX2 locus. J Natl Cancer Inst 2001;93:635-639.
190. Ahmed FE. Effect of diet on cancer and its progression in humans. J Env Sci Health 1992;C10:141-180.
191. Ingles SA, Haile RW, Henderson BE, et al. Strength of linkage disequilbrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomark Prev 1997;6:93-98.
192. Kim HS, Newcomb PA, Ulrich CM, et al. Vitamin D receptor polymorphism and the risk of colorectal adenoma: evidence of interaction with dietary D and calcium. Cancer Epidemiol Biomark Prev 2001;10:869-874.
193. Slattery ML, Yakumo K, Hoffman M, et al. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 2001;12:359-364.
194. Peters U, McGlynn KA, Catterjee N, et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenoma. Cancer Epidemiol Biomark Prev 2001;10:1267-1274.
195. Simon M, Bourel M, Genetet B, et al. Heridity of idiopathic haemochromatosis. Lancet 1977;1:706-709.
196. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary haemochromatosis: a HuGE review. Human genome epidemiology. Am J Epidemiol 2001;154:193-206.
197. van der ADL, van der Hel O, Roest M, et al. Heterozygosity for the Cys282Tyr mutation in the HHE gene and the risk of colorectal cancer (Netherlands). Cancer Causes Control 2003;14:541-545.
198. Nelson RL, Davis FG, Persky V, et al. Risk of neoplastic and other diseases among people with heterozygosity for hereditary chromatosis. Cancer 1995;76:875-879.
199. Beckman LE, van Landeghem GF, Sikström C, et al. Interaction between haemochromatosis and transferring receptor genes in different neoplastic disorders. Carcinogenesis 1999;20:1231-1233.
200. Macdonald GA, Tarish J, Whitehall VJ, et al. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys28Tyr haemochromatosis mutation. J Gastroenterol Hepatol 1999;14:1188-1191.
201. Altes A, Gimferrer E, Capella G, et al. Colorectal cancer and HFE gene mutations. Haematologica 1999;84:479-480.
202. Stoehlmacher J, Pat DJ, Zhang W, et al. A multivariate analysis of genomic polymorphism: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 2004;91:344-354.
203. Ulrich CM, Bigler J, Velicer CM, et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomark Prev 2000;9:1381-1385.
204. Marsh S, Collie-Duguid ES, Li T, et al. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999;58:310-312.
205. Luo HR, Lu XM, Yao YG, et al. Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 2002;40:41-51.
206. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics 2001;1:65-70.
207. Villafranca E, Okruzhnov Y, Dominguez MA, et al. A polymorphism of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001;19:1779-1786.
208. Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85:827-830.
209. Chen J, Hunter DJ, Stampfer MJ, et al. Poymorphism in the thymidylate synthase promoter enhancer region modifies the risk and survival of colorectal cancer. Cancer Epidemiol Biomark Prev 2003;12:958-962.
210. Butkiewicz D, Rusin M, Harris CC, et al. Identification of four nucleoside polymorphism in DNA repair genes: XPA and XPB (ERCC3) in Polish population. Human Mutat 2000;15:577-578.
211. Lum RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphism: effects on DNA repair proficiency. Carcinogenesis 2000;21:551-555.
212. Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione-S-transferase P1, T1 and M1 generic polymorphisms and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002;94:936-942.
213. 32P-DNA adducts in a sample of healthy subjects. Carcinogenesis; 2001;22:1437-1445.
214. Tranah GJ, Giovannucci E, Ma J, et al. XRCC2 and XRCC3 polymorphisms are not associated with risk of colorectal adenoma. Cancer Epidemiol Biomark Prev 2004;13:1090-1091.
215. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenetics 2004;5:835-843.
216. Ahmed FE. Mlecular markers that predict response to colon cancer therapy. Exp Rev Mol Diag 2005;5:353-375.
217. Chao A, Thun MJ, Connell CJ, et al. Meat consumption and risk of colorectal cancer. J Am Med Assoc 2005;293:172-182.
218. Murtaugh MA, Sweeney C, Ma K-N, et al. The CYP1A1 genotype may alter the association of meat consumption patterns and preparation with the risk of colorectal cancer in men and women. J Nutr 2005;135:179-186.
219. Murtaugh MA, Ma K-N, Sweeney C, et al. Meat consumption paterns and preparation, genetic variants of metabolic enzymes, and their association with rectal cancer in men and women. J Nutr 2004;134:776-784.
220. Turner F, Smith G, Sache C, et al. Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colon cancer. Int J Cancer 2004;112:259-264.
221. Mathew A, Sinha R, Burt R, et al. Meat intake and the recurrence of colorectal adenomas. Eur J Cancer Prev 2004;13:159-164.
222. Tiemersma EW, Voskuil DW, Bunschoten A, et al. Risk of colorectal adenoma in relation to meat consumption, meat preparation, and genetic susceprtibility in a Dutch population. Cancer Causes Control 2004;15:1-12.
223. Magagnotti C, Pastorelli R, Pozzi S, et al. Genetic polymorphism and modulation of 2-amino-1-methyl-6-phenylimidaz0[4,5,b]pyridine (PhIP)-DNA adducts in human lymphocytes. Int J Cancer 2003;107:878-884.
224. Ishibo N, Sinha R, Hein DW, et al. Genetic polymorphism in heterocyclic amine metabolism and risk of colorectal adenomas. Pharmacogenetics 2002;12:145-150.
225. Timersma EW, Kampman E, de Mesquita HB, et al. Meat consumption, cigarette smoking and genetic susceptibility in the etiology of colorectal cancer: results from a Dutch prospective study. Cancer Causes Control 2002;13:383-393.
226. Le Merchand L, Hankin JH, Pierce LM, et al. Well-done red meat, metabolic phenotypes and colorectal cancer in Hawaii. Mutat Res 2002;506-507:205-214.
227. Peters U, Sinha R, Bell DA, et al. Urinary mutagenesis and fried red meat intake: influence of cooking temperature, phenotype and genotype of metabolizing enzyme in a controlled feed study. Env Mol Mutagen 2004;43:53-74.
228. Roberts-Thomson IC, Ryan P, Khoo KK, et al. Diet, acetylator phenotype and risk of colorectal neoplasia. Lancet 1996;347:1372-1474.
229. Yeh C-C, Hsieh L-L, Tang R, et al. Vegetable/fruit, smoking, glutathione S-transferase are polymorphisms and risk for colorectal cancer in Taiwan. World J Gastroenterol 2005;11:1473-1480.
230. Tsubono Y, Otani T, Kobayashi M, et al. No association between fruit or vegetable consumption and the risk of colorectal cancer in Japan. Br J Cncer 2005;92:1782-1784.
231. Michels KB, Giovanucci E, Joshipura KJ, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000; 92: 17401752.
232. Voorrips LE, Goldbohm RA, van Poppel G, et al. Vegetable and fruit consumption and risk of colon and rectal cancer in a prospective cohort study: The Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol 2000;152:1081-1092.
233. Kim Y-I. Vegetables, fruits, and colorectal cancer risk: what should we believe. Nutr Res 2001;59:394-398.
234. Terry P, Giovannucci E,m Michels KB, et al. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst 2001;93:525-533.
235. International Agency for Cancer Research Working Group. IARC handbook on Cancer Prevention. Volume 8: Fruit and Vegetables. Lyon, France: IARC Press, 1997.
236. WCFR (World Cancer Research Fund). Food, Nutrition and the Prevention of Cancer: a Global Prespective. Washington, DC: American Institute for Cancer Research, 1997.
237. NAS (US National Academy of Sciences). Diet and Health. Institute of Medicine Committee on Diet and Health. Washington, DC: National Academy Press, 1989.
238. Jenab M, Ferrari P, Slimani N, et al. Association of nut and seed intake with colorectal cancer risk in the European Prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev 2004;13:1595-1603.
239. Di Leo A, Messa C, Cavallini A, et al. Estrogens and colorectal cancer. Curr Drug Targets Immune Endocr Metabol Disord 2001;1:1-12.
240. Soriguer FJ, Gonzalez-Romero S, Esteva I, et al. Does the intake of nuts and seeds alter the appearance of menarche? Acta Obstet Gynecol Scand 1995;74:455-461.
241. Tranah GJ, Giovannucci E, Ma J, et al. Epoxide hydrolase polymorphism, cigarette smoking and risk of colorectal adenoma in the Nurses' Health Study and the Health Professionals Follow-up Study. Carcinogenesis 2004;25:1211-1218.
242. Smith WA, Gupta RC. Determining befficacy of cancer chemopreventive agents using a cell-free system concomitant with DNA adduction. Mutat Res 1999;425:143-152.
243. Gonzales FJ, Kimura S. Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice. Mutat Res 2001;477:79-87.
244. Cortessis V, Siegmund K, Chen Q, et al. A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal cancer. Cancer Res 2001;61:2381-2385.
245. Ulrich CM, Bigler J, Whitton JA, et al. Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol Biomark Prev 2001;10:875-882.
246. Slattery ML, Edwards S, Curtin K, et al. Associations between smoling, passive smoking, GSTM-1, NAT2 and rectal cancer. Cancer Epidemiol Biomark Prev 2003;12:882-889.
247. Slattery ML, Potter KD, Samowitz W, et al. NAT2, GSTM-1, cigarette smoking and colon cancer. Cancer Epidemiol Biomark Prev 1998;7:1079-1084.
248. Gertig DM, Stampher M, Haiman C, et al. Glutathione S-transferase GSTM1 and GSTT1 polymorphism and colorectal cancer risk: a prospective study. Cancer Epidemiol Biomark Prev 1998;7:1001-1005.
249. Deakin M, Elder J, Hendricks C, et al. Glutathione S-transferase GSTT1A geno-types and susceptibility to cancer: studies of interaction with GSTM1 in lung, oral, gastric, and colorectal cancers. Carcinogenesis 1996;17:881-884.
250. van der Hel O, de Mesquita HBB, Sandkuijl L, et al. Rapid N-acetyltransferase 2 imputed phenotype and smoking may increase risk of colorectal cancer in women (Netherlands). Cancer Causes Control 2003;14:293-298.
251. Potter JD, Bigler J, Fosdick L, et al. Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphism. Cancer Epidemiol Biomark Prev 1999;8:69-75.
252. Smits KM, Benhamou S, Garte S, et al. Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. Int J Cancer 2004;110:266-270.
253. Doll R, Peto RE. causes of cancer: quantitative estimates of risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1197-1308.
254. Kushi L, Giovannucci E. Diet and cancer. Am J Med 1996;334:356-361.
255. Byers T. What can randomized controlled trials tells us about nutrition and cancer prevention? CA Cancer J Clin 1999;49:353-361.
256. Forman MR, Hursting SD, Umar A, et al. Nutrition and cancer prevention: a multidisciplinary perspective on human trials. Ann Rev Nutr 2004; 223-254.
257. Giovannucci E, Martinez ME. Tobacco, cholorectal cancer, and adenomas: a review of the evidence. J Natl Cancer Inst 1996;88:1717-1730.
258. Hofstad B, Almendingen K, Vatn M, et al. Growth and recurrence of colorectal polyps: A double-blind 3-year intervention with calcium and antioxidants. Digestion 1998;59:148-156.
259. Platz EA, Willett WC, Colditz GA, et al. Proportion of colon cacer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control 2000;11:579-588.
260. Trichopoulou A, Orfanos P, Norat T, et al. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. Br. Med J 2005; dui:10.1136/bmj38415.644155.8F.
261. Willett WC. Diet and cancer. An evolving practice. J Am Med Assoc 2005;293:233-234.
262. Wang T-L, Rago C, Silliman N, et al. Prevalence of somatic alterations in the colorectal cancer cell gene. Proc Natl Acad Sci USA 2002;99:3076-3080.
263. Cargill M, Ashuler D, Ireland J, et al. Characterization of single nucleotide polymorphisms in coding region of human genes. Nature Genet 1999;22:231-283.
264. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncer-tainties: lessons from the crypt. Development.1990;110:1001-1020.
265. Tomlinson I, Bodmer W. Selection, the mutation rate and cancer: ensuring that the tail will not wag. Nature Med 1999;5:11-12.
266. Loeb LA. A mutator phenotype in cancer. Cancer Research 2001;61:3230-3239.
267. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits." Proc Natl Acad Sci USA 2000;97:3352-3357.
268. Diergaarde B, Tiemersma EW, Braam H, et al. Dietary factors and truncating APC mutations in sporadic colorectal adenomas. Int J Cancer 2005;113:126-132.
269. Diegaarde B, Van Geloof WL, Van Muijen GNP, et al. Dietary factors and the occurrence of truncating APC mutations in sporadic colon carcinomas: a Dutch population-based study. Carcinogenesis 2003;24:283-290.
270. Samowitz WS, Powers MD, Spirio LN, et al. β-Catenin mutations are more frequent in small colorectal adenomas than in large adenomas and invasive carcinomas. Cancer Res 1999;59:1442-1444.
271. Woodage T, King SM, Wacholder S, et al. The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nature Genet 1998;20:62-65.
272. Starinsky S, Figer A, Ben-Asher E, et al. Genotype phenotype correlations in Israeli colorectal cancer patients. Int J Cancer 2005;124:58-73.
273. Slattery ML, Samowitz W, Ballard L, et al. A molecular variant of the APc gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer. Cancer Res 2001;61:1000-1004.
274. Leslie A, Pratt NR, Gillespie K, et al. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinoma. Cancer Res 2003;63:4656-4661.
275. Smith G, Casey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002;99:9433-9438.
276. Samowitz WS, Curtin K, Ma K-N, et al. Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 2004;99:579-602.
277. Slattery MI, Curtin K, Ma K, et al. Diet, activity, and lifestyle associations with p53 mutations in colon tumors. Cancer Epidemiol Biomark Prev 2002;11:541-548.
278. Urosevic N, Krtolica K, Skaro-Milic A, et al. Prevalence of G- to T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia. Int J Cancer 1993;54:249-254.
279. Slattery ML, Anderson K, Curtin K, et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutation Res 2001;483:73-81.
280. Martinez ME, Maltzman T, Marshall JR, et al. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 1999;59:5181-5185.
281. Slattery ML, Curtin K, Anderson K, et al. Associations between dietary intake and Ki-ras mutations in colon tumors: a population-based study. Cancer Res 2000;60:6935-6941.
282. Brink M, Weijenberg MP, de Goeie J AFPM, et al. Fat and K-ras mutations in sporadic colorectal cancer in The Neterlands Cohort Study. Carcinogenesis 2004;35:1619-1628.
283. Bautista D, Obrador A, Moreno V, et al. Ki-ras mutation modifies the protective effect of dietary monounsaturated fat and calcium on sporadic olorectal cancer. Cancer Epidemiol Biomark Prev 1997;6:57-61.
284. Kampman E, Voskuil DW, van Kraats AA, et al. Animal products and K-ras codon 12 and 13 mutations in colon carcinomas. Carcinogenesis 2000;21:307-309.
285. Martinez ME, Maltzman T, Marshall JR, et al. Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res 1999;59:5181-5185.
286. Kampnan E, Voskuil DW, van Kraats AA, et al. Animal products and K-ras codon 12 and 13 mutations in colon carcinoma. Carcinogenesis 2000;32:307-309.
287. Yashiro M, Carethers JM, Laghi L, et al. Genetic pathways in the evaluation of morphologically distinct colorectal neoplasms. Cancer Res 2001;61:2676-2683.
288. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancer to tumor location, stage, abd survival: a population-based study. Cancer Epidemiol Biomark Prev 2000;9:1193-1197.
289. Diergaarde B, Vrieling A, van kraats AA, et al. Cigarette smoking and genetic alterations in sporadic colon carcinoma. Carcinogenesis 2003;24:565-571.
290. Slattery ML, Curtin K, Anderson K, et al. Associations between cigarette smoking, lifestyle factors and microsatellite instability in colon tumors. J Nat Cancer Inst 2000;92:1831-1836.
291. Yang P, Cunningham JM, Halling KC, et al. Higher risk of mismatch repair-deficient colorectal cancer in alpha(1)-antitrypsin deficiency carriers and cigarette smokers. Mol Genet Metab 2000;71:639-645.
292. Slattery ML, Potter JD, Friedman GD, et al. Tobacco use and colon cancer. Int J Cancer 1997;70:259-264.
293. Bellone G, Carbone A, Tibaudi D, et al. Differential expression of transforming growth factor-β1, -β2 and β3 in human colon carcinoma. Eur J Cancer 2001;37:224-233.
294. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000;342:1350-1358.
295. Picon A, Gold LI, Wang J, et al. A subset of metastatic human colon cancers expresses elevated levels of transforming growh factor β1. Epidemiol Biomark Prev 1998;7:497-504.
296. Wells RG, Yankelev H, Lin HY, et al. Biosynthesis of the type I and type II TGF-β receptors. Implications for complex formation. J Bil Chem 1997; 272:; 11444-11451.
297. Raju J, McCarthy B, Bird RP. Steady state levels of transforming growth factor-β1 and β2 mRNA and protein expression are elevated in colon tumors in vivo irrespective of dietary lipid interactions. Int J Cancer 2002;100:635-641.
298. Rao CV, Hirose Y, Indraine C, et al. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-1933.
299. Yu H, Rohan T. Role of insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
300. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591-614.
301. Manousos O, Souglakos J, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999;83:15-17.
302. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Epidemiol Biomark Prev 2000;9:345-349.
303. Renehan AG, Jones J, Potten CS, et al. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344-1350.
304. Hunt KJ, Toniolo P, Akhmedkhanov A, et al. Insulin-like growth factor II and colorectal cancer in women. Epidemiol Biomark Prev 2002;11:901-905.
305. Probst-Hensch NM, Wang H, Goh VHH, et al. Determinants of circulating insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations in a cohort of Singapore men and women. Epidemiol Biomark Prev 2003;12:739-746.
306. Ames BN. A role for supplements in optimizing health: the metabolic tune-up. Arch Biochem Biophys 2004;423:227-234.
307. Kant AK. Consumption of energy-dense, nutrient-poor foods by adult Americans: nutritional and health implications: The Third National Health and Nutrition Examination Survery, 1988-1994. Am J Clin Nutr 2000;72:929-936.
308. Ames BN, Wakimoto P. Are vitamin and mineral deficiencies a major cancer risk? Nature Rev Cancer 2002;2:694-704.
309. Ames BN. DNA damage from micronutrient deficiencies is likely to be a najor cause of cancer. Mutat Res 2001;475:7-20.
310. Ho E, Courtemanche C, Ames BN. Zinc deficiency induces oxidative DNA damage and increases p53 expression in human lung fibroblasts. J Nutr 2003;133:2543-2548.
311. 6 and its mechanisms. Biochim Biophys Acta 2003;1647:127-130.
312. Mills PK, Beeson WL, Phillips RL, et al. Cancer incidence among California Seventh-day Adventists. Am J Clin Nutr 1994;59(Suppl):1136S-1142S.
313. National Cancer Institute Graphic. Why eat five? Natl Cancer Inst 1996;88:1314.
314. Popkin BM, Siega-Riz AM, Haines PS. Correction and revision of conclusions - dietary trends in the United States. N Engl J Med 1997;337:1846-1848.
315. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA. 1995;92:5256-5265.
316. Otter T, Otter T, Ro E, et al. Chromosome breaks and loss (micronuclei) by flow cytometry of human lymphocytes. FASEB J 2004;18:1069-1075.
317. Bailey LB. Wagner PA, Christakis GJ, et al. Dining, follacin and iron status and hematological findings in predominantly black elderly persons from urban low-income households. Am J Clin Nutr 1979;32:2346-2353.
318. Blount BC, Mack MM, Wehr C, et al. Folate deficiency causes uracil misincorporation into hhuman DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997;94:3290-3295.
319. Ahmed FE, Setlow RB. DNA repair in xeroderma pigmentosum cells treated with combinations of ultraviolet radiation and N-acetoxy-2-aetylaminofluorene. Cancer Res 1979;22:471-479.
320. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996;56:4862-4864.
321. 12, homocysteine status and chromosome damage rate in lymphocytes of older men. Carcinogenesis 1997;18:1329-1336.
322. Abrams SA. Nutritional rickets: an old disease returns. Nutr Rev 2002;60:111-115.
323. Holt PR, Arber N, Halmos B, et al. Colonic epithelial cell proliferation decreases with increase levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomark Prev 2002;11:113-119.
324. m): relevance to genetic disease and polymorphism. Am J Clin Nutr 2002;75:616-658.
325. Jiang Q, Ames BN. γ-Tochopherol, but not α-tochopherol, decreases pro-inflammatory eicosanoids and inflammation damage in rats. FASEB J 2003;17:816-822.
326. Ahmed FE. Role of oxidative stress in environmental carcinogenesis. J Env Sci Health 1999;C17:210-251.
327. Udilova N, Jurek D, Marian B et al. Induction of lipid peroxidation in biomembranes by dietary oil components. Food Chem Toxicol 2003;41:1481-1489.
328. Seifred HE, McDonald SS, Anderson DE, et al. The antioxifdant conundrum in cancer. Cancer Res 2003;63:4259-4298.
329. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
330. Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514.
331. Augenlicht L, Bordonaro M, Heerdt B, et al. Cellular mechanisms for risk and transformation. Ann NY Acad Sci 1999;889:20-31.
332. Augenlicht LH, Veclich A, Klampfer L, et al. Application of gene expression profiling to colon cell maturation, transformation and chemoprevention. J Nutr 2003;133:2410S-2416S.
333. Augenlicht L, Heerdt BG. Mitochondria: integrators in tumorigenesis? Nature Genet 2001;28:104-105.
334. m) is associated with steady-state mitochondrial activity and the effect to which colonic epithelial cells undergoes butyrate-mediated grown unrest and apoptosis. Cancer Res 2003;63:6311-6319.
335. Brenner C, Kroemer G. Mitochondria-like death signal integrators. Science 2000;289:1150-1151.
336. Augenlicht LH, Heerdt BG, Mariadason JM, et al. Environment-gene interactions in intestinal cancer. Eur J Cancer Prev 2002;11:S12-S17.
337. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
338. Croteau DL, Bohr VA. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J Biol Chem 1997;272:25409-25412.
339. Polyak K, Li Y, Zhu H, et al. Somatic mutations of the mitochondrial gene in human colorectal tumors. Nature Genet 1998;20:291-293.
340. Bird A. DNA methylation patterns and epigenetic memory. Gene Dev 2002;16:6-21.
341. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genet 2003;33(Suppl):245-250.
342. Waterland RA, Garza C. Potential mechanisms of metabolic imprinting that lead to chronic disease. Am J Clin Nutr 1999;69:179-197.
343. Rakyan VK, Preis J, Morgan HD, et al. The marks, mechanisms and meaning of epigenetic status in mammals. Biochem J 2001;356(Pt 1):1-16.
344. Jones PA. The DNA methylation paradox. Trend Genet 1999;15:34-39.
345. Waterland RA, Jirtle RL. Early nutrition, epigenetic changes at transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 2004;20:63-68.
346. Hushimshony T, Zhang J, Keshet I, et al. The role of DNA methylation in setting up chromatin structure during development. Nature Genet 2003;34:187-195.
347. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nature Rev Genet 2001;2:21-31.
348. Biniszkiewicz D, Ribnau J, Ransaboy B, et al. Overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality. Mol Cell Biol 2002;22:2124-2129.
349. Waterland RA, Garza C. Early postnatal nutrition determines adult pancreatic glucose-responsive insulin secretion and islet gene expression in rats. J Nutr 2002;132:357-369.
350. Kazazian HH Jr. Genetics. L1 retrotransposons shape the mammalian gene. Science 2000;289:1152-1156.
351. Greally JM. Short interspersed transposable elements (INEs) are excluded from imprinted regions in the human genome. Proc Natl Acad Sci USA 2002;99:327-339.
352. Surani MA. Reprogramming of genome function through epigenetic inheritance. Nature 2001;414:122-126.
353. Rakyan VK, Blewitt ME, Druker R, et al. Metastable epialleles in mammals. Trend Genet 2002;18:348-351.
354. Sakatani T, Wei M, Katoh M, et al. Epigeneis heterogeneity at repeated loci in normal populations. Biochem Biophys Res Commun 2001;283:1124-1132.
355. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-1795.
356. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigetic gene regulation. Mol Cell Biol 2003;23:5293-5300.
357. Gitan RS, Shi H, Chen CM, et al. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Cancer Res 2002;12:158-161.
358. Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-819.
359. Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998;58:1713-1718.
360. Sankila R, Alatonen LA, Jarvinen HJ, et al. Better survival in patients with MLH1-associated hereditary colorectal cancer. Gastroenterology 1996;110:682-687.
361. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-819.
362. Cawkwell L, Li D, Lewis FA, et al. Microsatellite instability in colorectal cancer: improved assessment using florescent polymerase chain reaction. Gastroenterology 1995;109:465-471.
363. Bubb VJ, Curtis LJ, Cunningham C, et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996;12:2641-2649.
364. Lukish JR, Muro K, DeNobile I, et al. Prognostic significance of DNA replication rrors in young patients with colorectal cancer. Ann Surg 1998;227:51-56.
365. Cawkwell L, Gary S, Murgatroyd H, et al. Choice of management strategy for colorectal cancer based on a diagnostic immunoistochemical test for defective mismatch repair. Gut 1999;45:409-415.
366. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 80 allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-1303.
367. Massa MJ, Iniesta P, Gonzalez-Quevedo R, et al. Differential prognosis of replication error phenotype and loss of heterozygosity in sporadic colorectal cancer. Eur J Cancer 1999;35:1676-1682.
368. Gryfe R, Kim H, Hsieh ETK, et al. Tumor microsatellite instability and clinical outcomes in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
369. Elsaleh H, Joseph D, Grieu F, et al. Association of tumor sites and sex with survival benefits from adjuvant chemotherapy of colorectal cancer. Lancet 2000;355:1745-1750.
370. Johannsdottir JT, Bergthorsson JT, Gretarsdottir S, et al. Replication error in colorectal carcinoma: association with loss of heterozygosity at mismatch repair loci and clinicppathological variables. Anticancer Res 1999;19:1821-1826.
371. Salahshor S, Kressner U, Fischer H, et al. Microsatellite instability in sporadic colorectal cancer is not an indepdent prognostic factor. Br J Cancer 1999;81:190-193.
372. Curran B, Lenehan K, Mulcahy H, et al. Replication error phenotype, clinicopathological variables and patient outcome in Dukes' B stage II (T3, N0, M0) colorectal cancer. Gut 2000;46:200-204.
373. Feeley KM, Fullard JF, Henegham MA, et al. Microsatellite instability in sporadic colorectal canrcinoma is not an indicator of prognosis. J Pathol 1999;188:14-17.
374. Ko JM, Cheung MH, Kwan MW, et al. Genomic instability and alterations in Apc, Mcc, and Dcc in Hong Kong patients with colorectal carcinoma. Int J Cancer 1999;84:404-409.
375. Slattery ML, Friedman GD, Potter JD, et al. A description of age, sex, and site distribution of colon carcinoma in three geographic areas. Cancer 1996;78:1666-1670.
376. Gryfe R, Redston M, Gallinger S. Microsatellite instability in colorectal cancer. N Engl J Med 2000;342:16908-1615.
377. Samowitz WS, Curtin K, Ma K-N et al. Microsatellite instability in sporadic colorectal cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomark Prev 2001;10:917-923.
378. Mori Y, Selaru FM, Sato F, et al. The imapact of microsatellite instability on the molecular phenotype of colorectal tumors. Cancer Res 2003;63:477-4582.
379. Fujiwara T, Stolker JM, Watanae T, et al. Accumulated clonal genetic alterations in familial and sporadic colorectal carcinoma with widespread instability in microsatellite sequences. Am J Pathol 1998;153:1063-1078.
380. Craanen ME, Block P, Offerhaus GJ, et al. Recent developments in hereditary nonpolyposis colon cancer. Scand J Gastroenterol 1996;218:92-97.
381. Tolbert DM, Noffsinger AE, Miller MA, et al. p53: immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Mol Pathol 1999;12:54-60.
382. Dix B, Robbins P, Carrello S, et al. Comparison of p53 gene mutation and protein overexpression in colorectal carcinomas. J Pathol 1998;184:390-395.
383. Baas IO, Mulder JR, Offerhaus GJ, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
384. Samowitz WS, Holden JA, Curtin K, et al. Inverse relationship between microsatellite instability in stable and K-ras and p53 alteration in colon cancer. Am J Pathol 2001;158:1517-1524.
385. Slattery ML, Potter JD, Curtin K, et al. Estrogen reduce and withdrawal of estrogen increase risk of microsatellite instability-postivr colon cancer. Cancer Res 2002;61:126-130.
386. Warthin AS. Heredity with reference to carcinoma. Arch Intern Med 1913;12:546-555.
387. Lynch HT, Krush AJ. Cancer family G revisited: 1895-1970. Cancer 1971;27:1505-1511.
388. Marra G, Boland CR. Hereditary nonpolyposis colorectal cancer: The syndrome, the gene, and historical perspectives. J Natl Cancer Inst 1995;87:1114-1125.
389. Butler WJ, Roberts-Thomson IC. Genetic disorders in gastroenterology and hepatology. J Gastroenterol Hepatol 2004;19:1215-1216.
390. Eady JJ, Wortley GM, Wormstone YM, et al. Variation in gene expression profiles of peripheral blood mononuclear cells from healthy volunteers. Physiol Genom 2005; doi:10.1153/physiolgenomics.00080.2005.